Manchester Capital Management’s Gilead Sciences GILD Stock Holding History

Manchester Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.85M	Buy	13,270 +137	+1%	+$19.2K	0.27%	56
2025 Q4	$1.61M	Sell	13,133 -427	-3%	-$51.9K	0.22%	69
2025 Q3	$1.51M	Sell	13,560 -934	-6%	-$106K	0.2%	74
2025 Q2	$1.61M	Sell	14,494 -485	-3%	-$51.6K	0.21%	75
2025 Q1	$1.68M	Sell	14,979 -20	-0.1%	-$2.06K	0.21%	79
2024 Q4	$1.39M	Sell	14,999 -7,579	-34%	-$682K	0.16%	88
2024 Q3	$1.89M	Buy	22,578 +483	+2%	+$36.9K	0.22%	68
2024 Q2	$1.52M	Buy	22,095 +778	+4%	+$51.9K	0.18%	75
2024 Q1	$1.56M	Sell	21,317 -525	-2%	-$40.4K	0.19%	78
2023 Q4	$1.77M	Buy	21,842 +185	+0.9%	+$14.4K	0.24%	65
2023 Q3	$1.62M	Buy	21,657 +468	+2%	+$36K	0.24%	62
2023 Q2	$1.63M	Buy	21,189 +135	+0.6%	+$10.8K	0.22%	70
2023 Q1	$1.75M	Sell	21,054 -200	-0.9%	-$16.6K	0.23%	63
2022 Q4	$1.82M	Buy	21,254 +27	+0.1%	+$2.14K	0.27%	53
2022 Q3	$1.31M	Sell	21,227 -1,000	-4%	-$63.1K	0.23%	63
2022 Q2	$1.37M	Hold	22,227	–	–	0.24%	60
2022 Q1	$1.32M	Hold	22,227	–	–	0.19%	72
2021 Q4	$1.61M	Hold	22,227	–	–	0.21%	71
2021 Q3	$1.55M	Hold	22,227	–	–	0.21%	70
2021 Q2	$1.53M	Hold	22,227	–	–	0.21%	70
2021 Q1	$1.44M	Sell	22,227 -815	-4%	-$52.6K	0.21%	75
2020 Q4	$1.34M	Sell	23,042 -385	-2%	-$23.2K	0.21%	74
2020 Q3	$1.48M	Sell	23,427 -150	-0.6%	-$10.4K	0.23%	60
2020 Q2	$1.81M	Sell	23,577 -100	-0.4%	-$7.66K	0.25%	47
2020 Q1	$1.77M	Buy	23,677 +15	+0.1%	+$1.04K	0.28%	44
2019 Q4	$1.54M	Buy	23,662 +1,920	+9%	+$125K	0.17%	67
2019 Q3	$1.38M	Hold	21,742	–	–	0.16%	67
2019 Q2	$1.47M	Sell	21,742 -315	-1%	-$20.7K	0.19%	63
2019 Q1	$1.43M	Buy	22,057 +2,275	+12%	+$151K	0.18%	61
2018 Q4	$1.4M	Hold	19,782	–	–	0.21%	50
2018 Q3	$1.53M	Hold	19,782	–	–	0.22%	47
2018 Q2	$1.4M	Buy	19,782 +7,541	+62%	+$533K	0.21%	50
2018 Q1	$923K	Sell	12,241 -4,841	-28%	-$385K	0.15%	68
2017 Q4	$1.22M	Buy	17,082 +10,000	+141%	+$759K	0.18%	52
2017 Q3	$574K	Hold	7,082	–	–	0.09%	108
2017 Q2	$501K	Sell	7,082 -40	-0.6%	-$2.66K	0.08%	113
2017 Q1	$484K	Hold	7,122	–	–	0.08%	117
2016 Q4	$510K	Sell	7,122 -75	-1%	-$5.58K	0.08%	116
2016 Q3	$569K	Sell	7,197 -15	-0.2%	-$1.22K	0.09%	112
2016 Q2	$602K	Hold	7,212	–	–	0.09%	105
2016 Q1	$662K	Hold	7,212	–	–	0.09%	94
2015 Q4	$730K	Hold	7,212	–	–	0.1%	90
2015 Q3	$708K	Hold	7,212	–	–	0.12%	71
2015 Q2	$844K	Sell	7,212 -475	-6%	-$51.9K	0.13%	64
2015 Q1	$754K	Sell	7,687 -3,506	-31%	-$356K	0.12%	71
2014 Q4	$1.05M	Buy	11,193 +210	+2%	+$21.7K	0.13%	64
2014 Q3	$1.17M	Sell	10,983 -1,097	-9%	-$107K	0.16%	54
2014 Q2	$1M	Buy	12,080 +1,456	+14%	+$113K	0.13%	68
2014 Q1	$753K	Sell	10,624 -630	-6%	-$49.4K	0.12%	90
2013 Q4	$845K	Hold	11,254	–	–	0.13%	84
2013 Q3	$708K	Sell	11,254 -176	-2%	-$10.5K	0.12%	91
2013 Q2	$586K	Buy	+11,430	New	+$596K	0.11%	92

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Manchester Capital Management's GILD Position: Q1 2026 in Review

Manchester Capital Management increased its Gilead Sciences (GILD) stake by 1% in Q1 2026, buying an estimated $19.2K and bringing the position to 13,270 shares worth $1.85M. The position accounts for 0.27% of the portfolio, ranked #56.

Manchester Capital Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.89M in Q3 2024. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Manchester Capital Management held 13,270 shares of Gilead Sciences worth $1.85M as of Q1 2026.
Manchester Capital Management bought 137 Gilead Sciences shares in Q1 2026, an estimated $19.2K.
Gilead Sciences made up 0.27% of Manchester Capital Management's portfolio in Q1 2026, its #56 holding.
Manchester Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
Manchester Capital Management's Gilead Sciences position peaked at $1.89M in Q3 2024.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.